Semaglutide vs Tirzepatide: Wegovy, Ozempic, Zepbound and Mounjaro Compared

Semaglutide and tirzepatide are the two names people compare most often in modern weight-loss medicine. Semaglutide is the active ingredient in Wegovy and Ozempic. Tirzepatide is the active ingredient in Zepbound and Mounjaro.

The short answer: tirzepatide usually wins on average weight loss. Semaglutide still matters because it has a huge evidence base, specific cardiovascular and metabolic labels, and may be the better-covered or better tolerated option for some people.

For brand-specific searches, read Zepbound vs Wegovy and Ozempic vs Wegovy.

Quick Comparison

Question	Semaglutide	Tirzepatide
Drug class	GLP-1 receptor agonist	Dual GIP / GLP-1 receptor agonist
Major brands	Wegovy, Ozempic, Rybelsus	Zepbound, Mounjaro
Weight-loss edge	Strong, but usually lower than tirzepatide in obesity comparisons	Highest average weight loss among approved injectable options
Diabetes use	Ozempic and Rybelsus are labeled for type 2 diabetes	Mounjaro is labeled for type 2 diabetes
Weight-management use	Wegovy is labeled for chronic weight management	Zepbound is labeled for chronic weight management
Main side effects	Nausea, vomiting, diarrhea, constipation, reflux and reduced appetite	Similar GI pattern; dose escalation is a common trouble point

Mechanism

Semaglutide activates one main incretin pathway: GLP-1. That improves glucose-dependent insulin signaling, suppresses appetite, slows gastric emptying and reduces food intake.

Tirzepatide activates GLP-1 and GIP receptors. The added GIP pathway is one reason tirzepatide tends to produce larger average weight loss and strong A1c reductions in trials.

That does not mean tirzepatide is automatically better for every person. Contraindications, tolerability, drug access, insurance and medical history matter more than a trial average.

Weight Loss Data

Comparison	Semaglutide result	Tirzepatide result	How to read it
Direct head-to-head obesity trial (SURMOUNT-5)	~13.7% average weight loss at 72 weeks (max tolerated 1.7 or 2.4 mg)	~20.2% average weight loss at 72 weeks (max tolerated 10 or 15 mg)	Tirzepatide superior on average weight loss in this open-label Phase 3b trial (NEJM).
Pivotal obesity trials	STEP 1 reported about 14.9% average weight loss at 68 weeks	SURMOUNT-1 reported up to about 20.9% at 72 weeks	Different trials, but the pattern still favors tirzepatide on weight.
Practical conclusion	Still a strong approved weight-loss medicine	Often the stronger average weight-loss choice	Individual response and side effects can flip the real-world answer.

Side Effects

Both drugs have a gastrointestinal side-effect profile:

• Nausea.
• Vomiting.
• Diarrhea.
• Constipation.
• Reflux, belching or appetite suppression that goes too far.
• Injection-site reactions.

Labels also warn about more serious risks, including pancreatitis signals, gallbladder problems, hypoglycemia when combined with insulin or insulin secretagogues, kidney injury in the setting of dehydration, and thyroid C-cell tumor warnings based on animal data.

For more detail, read GLP-1 side effects.

Which One Fits Which Case?

Scenario	Usually points toward	Why
Highest average weight loss is the priority	Tirzepatide / Zepbound	Head-to-head and pivotal obesity data favor tirzepatide.
Established cardiovascular disease plus overweight or obesity	Often semaglutide / Wegovy	Wegovy has a specific cardiovascular risk-reduction label in this setting.
Type 2 diabetes	Ozempic or Mounjaro	Both are diabetes products; coverage often decides.
Obstructive sleep apnea with obesity	Zepbound	Zepbound has a label in this obesity-related condition.
Bad nausea during escalation	Neither automatically	The answer may be slower titration, holding a dose, switching or stopping under medical guidance.

Labels and brands (do not mix them up)

Active ingredient	Weight-management brand	Diabetes brand	Notes
Semaglutide	Wegovy	Ozempic (injectable), Rybelsus (oral)	Same molecule family, different labeled doses and indications
Tirzepatide	Zepbound	Mounjaro	Dual agonist; separate pens and labeled schedules

Searching "Ozempic vs Mounjaro" is not identical to "Wegovy vs Zepbound." Brand pages: Ozempic vs Wegovy, Zepbound vs Wegovy.

Cardiovascular and specialty labels

Semaglutide (Wegovy) carries a cardiovascular risk-reduction indication in adults with established CVD and overweight/obesity — a reason some clinicians prefer it when that label matches the patient. Tirzepatide (Zepbound) has expanded obesity-related labeling (including obstructive sleep apnea in appropriate patients). Always verify the current USPI; labels change.

This is why "who wins on average pounds" is incomplete. Sometimes the better drug is the one whose label matches the comorbidity and is covered.

Cost, access and switching

Real-world choice often collapses to:

• Insurance formulary and prior authorization
• Supply availability
• Side-effect tolerance during titration
• Clinician familiarity and monitoring plan

Cost literacy: GLP-1 cost, cheapest GLP-1 for weight loss, GLP-1 coupon.

Switching between semaglutide and tirzepatide should be clinician-directed. There is no universal unit conversion. Residual GI effects and delayed gastric emptying mean aggressive "next day max dose" switches are a bad idea.

How this pairs with pipeline drugs

If the comparison is actually "tirzepatide vs the next thing," see tirzepatide vs retatrutide. Retatrutide is investigational; it does not replace either approved option today.

Titration and tolerability (why the “stronger” drug can fail)

Higher average efficacy is useless if the patient cannot stay on therapy. Both drugs require gradual dose escalation. Common clinical levers when GI symptoms spike:

• Delay the next escalation
• Hold at a lower maintenance dose if weight-loss goals allow
• Optimize meal size, fat content and hydration
• Rule out dehydration and gall bladder red flags
• Consider switching agents under supervision — not stacking

See GLP-1 side effects and GLP-1 dosage for weight loss for label-style context (educational, not a self-dosing manual).

Diabetes vs obesity decision frames

Primary goal	Often involves	Notes
Type 2 diabetes control + some weight loss	Ozempic or Mounjaro	Coverage and A1c targets dominate
Chronic weight management without diabetes	Wegovy or Zepbound	BMI/comorbidity eligibility on labels
Established CVD + overweight/obesity	Often Wegovy when label matches	CV risk-reduction indication is a differentiator
Obesity-related OSA	Zepbound when label matches	Check current indication language

Oral semaglutide footnote

Rybelsus is oral semaglutide for diabetes, not a simple substitute for Wegovy obesity dosing. Absorption rules (fasting, water volume, wait before food) make it a different practical product. Do not assume oral and injectable schedules interchange.

Myths

Myth	Better framing
Tirzepatide is “just a stronger Ozempic”	Different receptor profile (GIP+GLP-1) and different brands/labels
Semaglutide is obsolete	Still foundational; CV and access reasons keep it highly relevant
You can convert pens with a fixed ratio	No universal safe DIY conversion
Compounded “same peptide” equals the brand	Quality and legality differ — see compounded GLP-1 coverage

Choose X if / choose Y if

Lean toward	If…	Still check
Tirzepatide (Zepbound / Mounjaro)	Average weight-loss magnitude is the priority and dual-agonist therapy is appropriate	GI tolerance at higher maintenance doses; formulary tier
Semaglutide (Wegovy / Ozempic)	Established CVD risk-reduction labeling matches, or access/tolerance favors a pure GLP-1	Current USPI language and prior-auth rules
Stay / switch under a clinician	Side effects, plateau, supply gaps or new comorbidities change the picture	Not a forum mg conversion chart

Body composition and “muscle loss” noise

Large weight loss on either agent can include loss of fat and some lean mass. That is not unique marketing drama for one brand. What matters clinically is:

• How much total weight and metabolic risk improved
• Whether protein intake and resistance training are part of care
• How body composition was measured (DXA vs scale vs marketing claim)
• Whether the patient is elderly, sarcopenic or in a very aggressive deficit

Neither this page nor social media can assign a personal “muscle-safe” dose. See also class safety context in GLP-1 side effects.

Practical tools (math only)

Brand pens are labeled products. If you are only checking reconstitution arithmetic for educational research contexts, use:

• Reconstitution calculator
• Unit converter
• Accumulation calculator

Database profiles: semaglutide · tirzepatide. Pipeline next step: tirzepatide vs retatrutide.

Bottom Line

For weight loss alone, tirzepatide is usually the stronger bet on average. For specific cardiometabolic labels, semaglutide can still be the more relevant medicine. For diabetes, the practical choice is often whichever labeled product is covered, tolerated and appropriate for the patient.

Use peptides for weight loss for the broader category map and the peptide database for structured compound pages.

References

1. Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine.

2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine.

3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine.

4. Novo Nordisk. Wegovy prescribing information.

5. Eli Lilly. Zepbound prescribing information.